Host: Mario R. Nacinovich, Jr., MSc <br>

Guest: Michael R. Shafique, MD <br>


  <p>Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida. </p>

Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Special Considerations in NSCLC: Treating PD-L1 High Patients

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by

Medicine

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;Sponsored by

Share Special Considerations in NSCLC: Treating PD-L1 High Patients

Sign up to save your podcasts

Special Considerations in NSCLC: Treating PD-L1 High Patients

Special Considerations in NSCLC: Treating PD-L1 High Patients